Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-05-30
1997-03-11
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241341, 4241361, 4241391, 4241781, 4241921, 435 693, 4352523, 4351722, 4351723, 5303873, 53038825, 5303893, 536 234, 536 2353, A61K 39395
Patent
active
056098693
ABSTRACT:
Hybrid immunoglobulin-enzyme molecules are provided which are composed of antibodies, or derivatives or fragments thereof, which specifically bind an arterial or venous thrombus that are operably linked to the enzymatically active portions of thrombolytic enzymes such as plasminogen activators. In a preferred embodiment the hybrid molecules specifically bind to fibrin and have fibrinolytic activity. The hybrid molecules of the present invention may be produced by any means, including chemical conjugation, or by means of recombinant DNA, genetic engineering and/or hybridoma technology. Methods for making and using the molecules in diagnosis and therapy are also disclosed.
REFERENCES:
patent: 4273873 (1981-06-01), Sugitachi et al.
patent: 4368149 (1983-01-01), Masucho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4474893 (1984-10-01), Reading
patent: 4545988 (1985-11-01), Nakayama et al.
patent: 4600580 (1986-07-01), Smith
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4722903 (1988-02-01), Kudryk et al.
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4783330 (1988-11-01), Furie et al.
patent: 4833085 (1989-05-01), Schaumann et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5055289 (1991-10-01), Fincke et al.
patent: 5116613 (1992-05-01), Haber et al.
patent: 5256413 (1993-10-01), Haber et al.
patent: 5275812 (1994-01-01), Gold et al.
Angles-Cano, E. R., "Tissue Plasminogen Activator Determination with a Fibrin-Supported Film," 7-Enzymes 104:307, Abstract No. 104:144639d (1986).
Bode et al., "Characterization of an Antibody-Urokinase Conjugate," J. Biol. Chem. 262(22):10819-10823 (1987).
Bode et al., "Enhanced Thrombolysis in Plasma and In Vivo by Single-Chain Urokinase-Type Plasminogen Activator (scuPA) Conjugated To An Antifibrin Antibody," Trans. Assoc. Am. Phys. 102:7-12 (1989).
Bode et al., "Future Directions in Plasminogen Activator Therapy," Clin. Cardiol. 13:375-381 (1990).
Bode et al., "Improving on Nature: Antibody-Targeted Enzymes" in:The Year in Immunology, (Cruse and Lewis, eds.), S. Karger, Basel, Switzerland, vol. 6:185-196 (1990).
Bode et al., "Platelet-Targeted Fibrinolysis Enhances Clot Lysis and Inhibits Platelet Aggregation," Circulation 84(2):805-813 (1991).
Bode et al., "Targeting of Single-Chain Urokinase Plasminogen Activator By Conjugation To An Antiplatelet Antibody Results in Enhanced Clot Lysis," Transactions of the Assoc. of American Physicians 104:29-31 (1991).
Bode et al., "Purifying Antibody-Plasminogen Activator Conjugates," Bioconjugate Chemistry 3(4):269-272 (1992).
Bode et al., "Antifibrin-Urokinase Complex" in: Facts and Hopes in Thrombolysis and Acute Myocardial Infarction, (Effert et al. eds.), Steinkopff Verlag, Darmstadt, pp. 35-41 (1986).
Bode et al., "Conjugation to Antifibrin Fab' Enhances Fibrinolytic Potency of Single-Chain Urokinase Plasminogen Activator," Circulation 81:1974-1980 (1990).
Bode et al., "Characterization of an Antibody-Urokinase Conjugate," Journal of Biological Chemistry 272(22):10819-10823 (1987).
Bode et al., "Antibody-Directed Urokinase: A Specific Fibrinolytic Agent," Science 229:765-767 (1985).
Bode et al., "Thrombolysis by a Fibrin-Specific Antibody Fab'-Urokinase Conjugate," J. Mol. Cell. Cardiol. 19:335-341 (1987).
Bode et al., "Conjugation to an Antifibrin Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase (scuPA)," Clinical Research 36(3):203A (1988).
Bode et al., "Antibody-Directed Fibrinolysis," Journal of Biological Chemistry 264(2):944-948 (1989).
Bosnjakovic et al., "Radiolabelled Anti-Human Fibrin Antibody: A New Thrombus-Detecting Agent", The Lancet pp. 452-454 (Feb. 26, 19770.
Boss et al., "Assembly of functional antibodies from immunoglobul in heavy and light chains synthesized in E. coli", Nucl. Acid Res. 12(9):3791-3806 (1984).
Boulianne et al., "Production of Functional Chimeric Mouse/Human Antibody," Nature 312:643-646 (1984).
Branscomb et al., "Bispecific Antibodies that Bind Both Tissue Plasminogen Activator (t-PA) and Fibrin," Clinical Research 35(3):264A (1987).
Branscomb et al., "Bispecific Monoclonal Antibodies Produced by Somatic Cell Fusion Increase the Potency of Tissue Plasminogen Activator," Thrombosis and Hemostasis 64(2):260-266 (1990).
Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments," Science 229:81-83 (1985).
Charpie et al., "Enhancement of Fibrinolysis by Single Chain Urokinase (scuPA) with a Bifunctional Antibody Having Both Fibrin and scuPA Specificities," Clinical Research 36(3):436A (1988).
Charpie et al., "A Bispecific Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase," Biochemistry 29(27):6374-6378 (1990).
Charpie et al., "A Sequence-Dependent Monoclonal Antibody Specific for Single-Chain Urokinase," Biochemical and Biophysical Research Communications 152(2):910-915 (1988).
Collen et al., "Thrombolytic and Pharmacokinetic Properties of Conjugates of Urokinase-type Plasminogen Activator with a Monoclonal Antibody Specific for Crosslinked Fibrin," Fibrinolysis 3:197-202 (1989).
Collen et al., "Activation of Plasminogen by Pro-Urokinase," J. Biol. Chem. 261(3):1259-1266 (1986).
Deans et al., "Expression of an Immoglobul in Heavy Chain Gene Transfected into Lymphocytes," Proc. Natl. Acad. Sci. USA 81:1292-1296 (1984).
Declerck et al., "Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis," Thrombosis and Hemostasis 58(4):1024-1029 (1987).
Dewerchin et al., "Effect of Chemical Conjugation of Recombinant Single-Chain urokinase-Type Plasminogen Activator with Monoclonal Antiplatelet Antibodies on Platelet Aggregation and on Plasma Clot Lysis In Vitro and In Vivo," Blood 78(4):1005-1018 (1991).
Dewerchin et al., "Biochemical Properties of Conjugates of Urokinase-Type Plasminogen Activator with a Monoclonal Antibody Specific for Cross-Linked Fibrin," Eur. J. Biochem. 185:141-149 (1989).
Derwerchin et al., "Enhancement of the Thrombolytic Potency of Plasminogen Activators by Conjugation with Clot-Specific Monoclonal Antibodies," Bioconjugate Chemistry 2(5):293-300 (1991).
Dewerchin et al., "Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase," Thrombosis and Hemostasis 68(2):170-179 (1992).
Dillman et al., "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine 111(7):592-603 (1989).
Doolittle, R. F., Fibrinogen and Fibrin, The Plasma Proteins: Structure, Function and Genetic Control (Putnam, F. W., ed.) Academic Press, 3rd Edition, N.Y., N.Y., 2: 109-156 (1975).
Dorai et al., "The Effect of Dihydrofolate Reductase-Mediated Gene Amplification on the Expression of Transfected Imunoglobulin Genes," Journal of Immunology 139(12):4232-4241 (1987).
Duberstein, R., "Scientists Develop New Technique for Producing Bispecific Monoclonals," Genet. Eng. News 6(1):22-23 (1986).
Fisher et al., "Isolation and Characterization of the Human Tissue-Type Plasminogen Activator Structural Gene Including Its 5' Flanking Region," Journal of Biological Chemistry 260(20):11223-11230 (1985).
Grossman et al., "Imaging of Fresh and Aged Venous Thrombi in the Dog with I-131 Monoclonal Antibody Specific for the NH.sub.2 -Terminal Region of Fibrin", J. Nucl. Med. 26(5):p. 21, Abstract No. 76 (1985).
Guenzler et al., "Chemical, Enzymological and Pharmacological Equivalence of Urokinase Isolated from Genetically Transformed Bacteria and Human Urine," Chemical Abstracts 103:40, Abstract No. 401b (1985).
G unzler et al., "Chemical, Enzymological and Pharmacological Equivalence of Urokinases Isolated from Genetically Transformed Bacteria and Human Urine," Arzneim. -Forsch./Drug Res.l 35(I), Nr. 3:652-662 (1985).
Gurewich et al., "Effective and Fibrin-specific Clot Lysis by a Zymogen Precursor Form of Urokinase (Pro-u
Haber Edgar
Quertermous Thomas
Runge Marschall S.
Nucker Christine M.
Scheiner Laurie
The General Hospital Corporation
LandOfFree
Hybrid immunoglobulin-thrombolytic enzyme molecules which specif does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid immunoglobulin-thrombolytic enzyme molecules which specif, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid immunoglobulin-thrombolytic enzyme molecules which specif will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-441312